“At Altasciences, we already help sponsors move from first safety assessment to proof of concept with speed and precision,” said Marie-Hélène Raigneau, CEO of Altasciences. “By embedding Certara’s modeling capabilities into our platform, we can further inform critical decisions earlier and with greater confidence. This collaboration is about reducing uncertainty at the moments that matter most.”
“This partnership unlocks new opportunities to improve early development decisions for biotech sponsors and their investors,” said Jon Resnick, CEO of Certara. “By embedding modeling and simulation directly into execution, we enable faster, more informed decision-making that ultimately benefits patients.”
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical study programs, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
Certara（サターラ）について
サターラは、モデリング＆シミュレーション・ソフトウェアと技術を用いて、従来の創薬・開発を変革し、医薬品をよりスピーディーに患者さんに届けることをミッションとしています。製薬、教育機関、規制当局のお客様 2,600人以上、70ヵ国にてサターラの技術やサービスが活用されています。Visit us at www.certara.com.
サターラの問い合わせ先：
Sheila Rocchio
[email protected]
報道機関の皆様：
赤津笑美 (emi.akatsu@certara.com)
[email protected]
